IOL Chemicals and Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from IOL Chemicals and Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 1 of the last 3 years; profit grew in 1 of 3. Less steady than 94% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹183Over the last 3 years, every ₹100 of reported profit came with ₹183 of operating cash.
Higher than 84% of Healthcare companies in India.
Self-Funding Ratio
1.0×Over the last 3 years its own operating cash covered its investment spending (capex) 1.0 times.
Lower than 63% of Healthcare companies in India.
Cash Locked Ratio
₹20For every ₹100 of sales, ₹20 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹22 tied up three years earlier.
Less money tied up than 60% of Healthcare companies in India.
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 94% of Healthcare companies in India.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by +5% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
+5% / +28%In 3 years sales changed by +5% while total assets changed by +28%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
1.6×Debt due within a year is covered 1.6 times by its yearly operating cash.
Higher than 56% of Healthcare companies in India.
Cash Cushion Ratio
+1%Cash, after subtracting all debt, equals 1% of its market value (net cash).
Higher than 61% of Healthcare companies in India.
Tangible Assets Ratio
99%Of every ₹100 the company owns, ₹99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 67% of Healthcare companies in India.
Tangible Net Worth Ratio
99%Of every ₹100 of net worth, ₹99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 68% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
IOL Chemicals and Pharmaceuticals Limited owes ₹0.30 for every ₹1 it owns. Net profit rose 36% in the year to Mar 2026, and shrank 0% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
30.0Investors pay ₹30.0 for every ₹1 of IOL Chemicals and Pharmaceuticals Limited's yearly profit, lower than 64% of Healthcare companies in India.
P/B ratio
2.80The share price is 2.80 times IOL Chemicals and Pharmaceuticals Limited's book value per share, lower than 74% of Healthcare companies in India.
Market cap
₹5,030 CrThe total market value of all of IOL Chemicals and Pharmaceuticals Limited's shares at today's price (share price × number of shares), smaller than 51% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹1,799 CrWhat IOL Chemicals and Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹61.27Net worth divided by the number of shares. The share price of ₹171.36 is 2.8 times this, which is the P/B above.
Return on equity (ROE)
9.3%IOL Chemicals and Pharmaceuticals Limited earned 9.3% on its shareholders' money over the last year, lower than 70% of Healthcare companies in India.
Owes vs Owns
0.30×IOL Chemicals and Pharmaceuticals Limited owes ₹0.30 for every ₹1 it owns (low), lower than 67% of Healthcare companies in India.
Dividend yield
0.50%IOL Chemicals and Pharmaceuticals Limited pays 0.50% of its share price as dividends a year, higher than 63% of dividend-paying Healthcare companies in India.
Revenue growth
+12%Revenue rose 12% in the year to Mar 2026, and grew 2% a year on average over 3 years.
Profit growth
+36%Net profit rose 36% in the year to Mar 2026, and shrank 0% a year on average over 3 years.
Profit margin
6.0%IOL Chemicals and Pharmaceuticals Limited keeps ₹6 of every ₹100 of revenue as net profit.
Cash quality
1.6×Cash from IOL Chemicals and Pharmaceuticals Limited's business was 1.6× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
19.0×IOL Chemicals and Pharmaceuticals Limited's operating profit covered its interest costs 19.0 times in the year to Mar 2026.
Cash vs debt
Net cashIOL Chemicals and Pharmaceuticals Limited held ₹26 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is IOL Chemicals and Pharmaceuticals Limited's P/E ratio?
Investors pay ₹30.0 for every ₹1 of IOL Chemicals and Pharmaceuticals Limited's yearly profit, lower than 64% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For IOL Chemicals and Pharmaceuticals Limited: ₹5,030 Cr ÷ ₹1,799 Cr (31 Mar 2026) = 2.8.
What is IOL Chemicals and Pharmaceuticals Limited's return on equity?
IOL Chemicals and Pharmaceuticals Limited earned 9.3% on its shareholders' money over the last year, lower than 70% of Healthcare companies in India.
How much does IOL Chemicals and Pharmaceuticals Limited owe compared with what it owns?
IOL Chemicals and Pharmaceuticals Limited owes ₹0.30 for every ₹1 it owns (low), lower than 67% of Healthcare companies in India.
Does IOL Chemicals and Pharmaceuticals Limited pay a dividend?
Yes. IOL Chemicals and Pharmaceuticals Limited pays 0.50% of its share price as dividends a year, higher than 63% of dividend-paying Healthcare companies in India.
Is IOL Chemicals and Pharmaceuticals Limited's revenue growing?
Revenue rose 12% in the year to Mar 2026, and grew 2% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.